Skálová A, Hyrcza MD, Leivo I (2022) Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1):40–53. https://doi.org/10.1007/s12105-022-01420-1

Article  PubMed  PubMed Central  Google Scholar 

Xu B, Dogan S, Haroon Al Rasheed MR, Ghossein R, Katabi N (2019) Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum Pathol 93:30–36. https://doi.org/10.1016/j.humpath.2019.08.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ et al (2018) A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer 143(4):758–766. https://doi.org/10.1002/ijc.31353

Article  CAS  PubMed  PubMed Central  Google Scholar 

McAfee JL, Hoda RS, Hoyle C, McCoy L, Sprague C, Reddy CA et al (2023) ERBB2 amplification and HER2 expression in salivary duct carcinoma: evaluation of scoring guidelines and potential for expanded anti-HER2 therapy. Mod Pathol 36(10):100273. https://doi.org/10.1016/j.modpat.2023.100273

Article  PubMed  Google Scholar 

Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M et al (2015) Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol 39(5):705–713. https://doi.org/10.1097/pas.0000000000000413

Article  PubMed  Google Scholar 

Katabi N, Xu B, Jungbluth AA, Zhang L, Shao SY, Lane J et al (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72(2):285–293. https://doi.org/10.1111/his.13341

Article  PubMed  Google Scholar 

Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M et al (2018) Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck 40(3):605–613. https://doi.org/10.1002/hed.25035

Article  PubMed  Google Scholar 

Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37(2):125–134. https://doi.org/10.1200/jco.18.00545

Article  CAS  PubMed  Google Scholar 

Can NT, Lingen MW, Mashek H, McElherne J, Briese R, Fitzpatrick C et al (2018) Expression of hormone receptors and HER-2 in benign and malignant salivary gland tumors. Head Neck Pathol 12(1):95–104. https://doi.org/10.1007/s12105-017-0833-y

Article  PubMed  Google Scholar 

Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW et al (2016) Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res 22(18):4623–4633. https://doi.org/10.1158/1078-0432.Ccr-16-0637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho AL (2021) Androgen receptor pathway in salivary gland cancer. J Clin Oncol 39(36):4069–4072. https://doi.org/10.1200/jco.21.01983

Article  PubMed  Google Scholar 

Dalin MG, Watson PA, Ho AL, Morris LG (2017) Androgen receptor signaling in salivary gland cancer. Cancers (Basel) 9(2):17. https://doi.org/10.3390/cancers9020017

Article  CAS  PubMed  Google Scholar 

Ferguson DC, Momeni Boroujeni A, Zheng T, Mohanty AS, Ho AL, Arcila ME et al (2022) ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. Mod Pathol 35(7):895–902. https://doi.org/10.1038/s41379-021-00999-0

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122 (MP 16)

Article  CAS  PubMed  Google Scholar 

Alotaibi AM, Alqarni MA, Alnobi A, Tarakji B (2015) Human epidermal growth factor receptor 2 (HER2/neu) in salivary gland carcinomas: a review of literature. J Clin Diagn Res 9(2):Ze04–Ze08. https://doi.org/10.7860/jcdr/2015/11289.5572

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks WL Jr, Rigual NR et al (2014) Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck 36(5):694–701. https://doi.org/10.1002/hed.23350

Article  PubMed  Google Scholar 

Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC et al (2018) Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head Neck 40(12):E100–E106. https://doi.org/10.1002/hed.25392

Article  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. https://doi.org/10.1056/NEJMoa2203690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu B, Haroon Al Rasheed MR, Antonescu CR, Alex D, Frosina D, Ghossein R et al (2020) Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion. Histopathology 76(3):375–382. https://doi.org/10.1111/his.13981

Article  PubMed  Google Scholar 

Bishop JA, Yonescu R, Batista D, Begum S, Eisele DW, Westra WH (2013) Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol 44(10):1982–1988. https://doi.org/10.1016/j.humpath.2013.03.017

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skalova A (2013) Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol 7(Suppl 1):S30–S36. https://doi.org/10.1007/s12105-013-0455-y

Article  PubMed  Google Scholar 

Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S et al (2015) An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 5(10):1049–1057. https://doi.org/10.1158/2159-8290.Cd-15-0443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su YJ, Lee YH, Jin YT, Hsieh MS (2022) Using pan-TRK and RET immunohistochemistry for the detection of fusion types of salivary gland secretory carcinoma. Appl Immunohistochem Mol Morphol 30(4):264–272. https://doi.org/10.1097/pai.0000000000001003

Article  CAS  PubMed  Google Scholar 

Skálová A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RH et al (2014) Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol 38(1):23–33. https://doi.org/10.1097/pas.0000000000000088

Article  PubMed  Google Scholar 

Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21(4):531–540. https://doi.org/10.1016/s1470-2045(19)30856-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amatu A, Sartore-Bianchi A, Siena S (2016) NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1(2):e000023. https://doi.org/10.1136/esmoopen-2015-000023

Article  PubMed  PubMed Central  Google Scholar 

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731–739. https://doi.org/10.1056/NEJMoa1714448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58–66. https://doi.org/10.1016/j.pharmthera.2017.02.006

Article  CAS  PubMed  Google Scholar 

Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A et al (2016) Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22(24):6061–6068. https://doi.org/10.1158/1078-0432.Ccr-15-2568

Article  CAS  PubMed  Google Scholar 

Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M et al (2016) What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 27(5):920–926. https://doi.org/10.1093/annonc/mdw042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R et al (2016) Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 15(4):628–639. https://doi.org/10.1158/1535-7163.Mct-15-0758

Article  CAS  PubMed